Distinct epidemiology and resistance mechanisms affecting ceftolozane/tazobactam in Pseudomonas aeruginosa isolates recovered from ICU patients in Spain and Portugal depicted by WGS
| UDC.coleccion | Investigación | |
| UDC.departamento | Fisioterapia, Medicina e Ciencias Biomédicas | |
| UDC.endPage | 379 | |
| UDC.grupoInv | Investigación en Microbiología (INIBIC) | |
| UDC.institutoCentro | INIBIC - Instituto de Investigacións Biomédicas de A Coruña | |
| UDC.issue | 2 | |
| UDC.journalTitle | Journal of Antimicrobial Chemotherapy | |
| UDC.startPage | 370 | |
| UDC.volume | 76 | |
| dc.contributor.author | Hernández-García, Marta | |
| dc.contributor.author | García-Castillo, María | |
| dc.contributor.author | García-Fernández, Sergio | |
| dc.contributor.author | Melo-Cristino, José | |
| dc.contributor.author | Pinto, Margarida Feijó | |
| dc.contributor.author | Gonçalves, Elsa | |
| dc.contributor.author | Alves, Valquíria | |
| dc.contributor.author | Vieira, Ana Raquel | |
| dc.contributor.author | Ramalheira, Elmano | |
| dc.contributor.author | Sancho, Luísa | |
| dc.contributor.author | Diogo, José | |
| dc.contributor.author | Ferreira, Rui | |
| dc.contributor.author | Silva, Tania | |
| dc.contributor.author | Chaves, Catarina | |
| dc.contributor.author | Bou, Germán | |
| dc.contributor.author | Cercenado, Emilia | |
| dc.contributor.author | Delgado-Valverde, Mercedes | |
| dc.contributor.author | Oliver, Antonio | |
| dc.contributor.author | Pitart, Cristina | |
| dc.contributor.author | Rodríguez-Lozano, Jesús | |
| dc.contributor.author | Tormo, Nuria | |
| dc.contributor.author | Romano, Joao | |
| dc.contributor.author | Pássaro, Leonor | |
| dc.contributor.author | Paixao, Laura | |
| dc.contributor.author | López-Mendoza, Diego | |
| dc.contributor.author | Díaz-Regañón, Jazmín | |
| dc.contributor.author | Cantón, Rafael | |
| dc.date.accessioned | 2025-10-30T10:15:04Z | |
| dc.date.available | 2025-10-30T10:15:04Z | |
| dc.date.issued | 2020-10-25 | |
| dc.description.abstract | [Abstract] Objectives: To analyse the epidemiology, the resistome and the virulome of ceftolozane/tazobactam-susceptible or -resistant Pseudomonas aeruginosa clinical isolates recovered from surveillance studies in Portugal (STEP, 2017-18) and Spain (SUPERIOR, 2016-17). Methods: P. aeruginosa isolates were recovered from intra-abdominal, urinary tract and lower respiratory tract infections in ICU patients admitted to 11 Portuguese and 8 Spanish hospitals. MICs were determined (ISO-standard broth microdilution, EUCAST 2020 breakpoints). A subset of 28 ceftolozane/tazobactam-resistant P. aeruginosa isolates were analysed and compared with 28 ceftolozane/tazobactam-susceptible P. aeruginosa strains by WGS. Results: Clonal complex (CC) 235 (27%) and CC175 (18%) were the most frequent, followed by CC244 (13%), CC348 (9%), CC253 (5%) and CC309 (5%). Inter-hospital clonal dissemination was observed, limited to a geographical region (CC235, CC244, CC348 and CC253 in Portugal and CC175 and CC309 in Spain). Carbapenemases were detected in 25 isolates (45%): GES-13 (13/25); VIM type (10/25) [VIM-2 (4/10), VIM-20 (3/10), VIM-1 (2/10) and VIM-36 (1/10)]; and KPC-3 (2/25). GES-13-CC235 (13/15) and VIM type-CC175 (5/10) associations were observed. Interestingly, KPC-3 and VIM-36 producers showed ceftolozane/tazobactam-susceptible phenotypes. However, ceftolozane/tazobactam resistance was significantly associated with GES-13 and VIM-type carbapenemase production. Six non-carbapenemase producers also displayed ceftolozane/tazobactam resistance, three of them showing known ceftolozane/tazobactam resistance-associated mutations in the PBP3 gene, ftsI (R504C and F533L). Overall, an extensive virulome was identified in all P. aeruginosa isolates, particularly in carbapenemase-producing strains. Conclusions: GES-13-CC235 and VIM type-CC175 were the most frequent MDR/XDR P. aeruginosa clones causing infections in Portuguese and Spanish ICU patients, respectively. Ceftolozane/tazobactam resistance was mainly due to carbapenemase production, although mutations in PBP-encoding genes may additionally be involved. | |
| dc.description.sponsorship | The study was funded by MSD Portugal (protocol VP6918) and MSD Spain (protocol MSD-CEF-2016-01). This study was also supported by Plan Nacional de I + D + i 2013–16 and Instituto de Salud Carlos III, Subdirección General de Redes y Centros de Investigación Cooperativa, Ministerio de Economía, Industria y Competitividad, Spanish Network for Research in Infectious Diseases [RD16/0016/0001, RD16/0016/0004, RD16/0016/0006, RD16/0016/0007, RD16/0016/0010 and REIPI RD16/0016/0011], co-financed by the European Development Regional Fund ‘A way to achieve Europe’ (EDRF), Operative Program Intelligent Growth 2014–20. M.H.-G. is supported by a research contract from a European Project [IMI-JU-9–2013, Ref. iABC - 115721–2]. | |
| dc.identifier.citation | Hernández-García M, García-Castillo M, García-Fernández S, Melo-Cristino J, Pinto MF, Gonçalves E, Alves V, Vieira AR, Ramalheira E, Sancho L, Diogo J, Ferreira R, Silva T, Chaves C, Bou G, Cercenado E, Delgado-Valverde M, Oliver A, Pitart C, Rodríguez-Lozano J, Tormo N, Romano J, Pássaro L, Paixão L, López-Mendoza D, Díaz-Regañón J, Cantón R; STEP and SUPERIOR study groups. Distinct epidemiology and resistance mechanisms affecting ceftolozane/tazobactam in Pseudomonas aeruginosa isolates recovered from ICU patients in Spain and Portugal depicted by WGS. J Antimicrob Chemother. 2021 Jan 19;76(2):370-379. | |
| dc.identifier.doi | 10.1093/jac/dkaa430 | |
| dc.identifier.issn | 0305-7453 | |
| dc.identifier.uri | https://hdl.handle.net/2183/46187 | |
| dc.language.iso | eng | |
| dc.publisher | Oxford University Press | |
| dc.relation.projectID | info:eu-repo/grantAgreement/MINECO//RD16%2F0016%2F0001/ES/RED ESPAÑOLA DE INVESTIGACIÓN EN PATOLOGÍAS INFECCIOSAS/ | |
| dc.relation.projectID | info:eu-repo/grantAgreement/MINECO//RD16%2F0016%2F0004/ES/RED ESPAÑOLA DE INVESTIGACIÓN EN PATOLOGÍAS INFECCIOSAS/ | |
| dc.relation.projectID | info:eu-repo/grantAgreement/MINECO//RD16%2F0016%2F0006/ES/RED ESPAÑOLA DE INVESTIGACIÓN EN PATOLOGÍAS INFECCIOSAS/ | |
| dc.relation.projectID | info:eu-repo/grantAgreement/MINECO//RD16%2F0016%2F0007/ES/RED ESPAÑOLA DE INVESTIGACIÓN EN PATOLOGÍAS INFECCIOSAS/ | |
| dc.relation.projectID | info:eu-repo/grantAgreement/MINECO//RD16%2F0016%2F0010/ES/RED ESPAÑOLA DE INVESTIGACIÓN EN PATOLOGÍAS INFECCIOSAS/ | |
| dc.relation.projectID | info:eu-repo/grantAgreement/MINECO//RD16%2F0016%2F0011/ES/RED ESPAÑOLA DE INVESTIGACIÓN EN PATOLOGÍAS INFECCIOSAS/ | |
| dc.relation.uri | https://doi.org/10.1093/jac/dkaa430 | |
| dc.rights | This is a pre-copyedited, author-produced version of an article accepted for publication in Journal of Antimicrobial Chemotherapy following peer review. The version of record is available online at Oxford Academic web page. | |
| dc.rights.accessRights | open access | |
| dc.subject | Pseudomonas infections | |
| dc.subject | Pseudomonas aeruginosa | |
| dc.title | Distinct epidemiology and resistance mechanisms affecting ceftolozane/tazobactam in Pseudomonas aeruginosa isolates recovered from ICU patients in Spain and Portugal depicted by WGS | |
| dc.type | journal article | |
| dc.type.hasVersion | AM | |
| dspace.entity.type | Publication | |
| relation.isAuthorOfPublication | 909e08d1-6ed1-4b99-9e9e-c64eb72e7dea | |
| relation.isAuthorOfPublication.latestForDiscovery | 909e08d1-6ed1-4b99-9e9e-c64eb72e7dea |

